基于组分合理性分析高血压复方药物

doi:10.19803/j.1672-8629.20240278

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 973-977.
DOI: 10.19803/j.1672-8629.20240278

• 复方与联合用药安全性评价专栏（二） • 上一篇下一篇

基于组分合理性分析高血压复方药物

郭姝姝^1,2, 江海燕², 范潇予², 李万芳^2,3, 包捷^2,3, 马恩龙^1#, 靳洪涛^2,3,4,*

¹沈阳药科大学生命科学与生物制药学院,辽宁沈阳 110016;
²中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京 100050;
³北京协和建昊医药技术开发有限责任公司,北京 100176;
⁴国家药品监督管理局创新药物安全研究与评价重点实验室,北京 102206

收稿日期:2024-04-28 出版日期:2024-09-15 发布日期:2024-09-14
通讯作者: ^*靳洪涛,男,研究员·博导,药物毒理学。E-mail: jinhongtao@imm.ac.cn。^#为共同通信作者。
作者简介:郭姝姝,女,在读硕士,药理学。
基金资助:
国家自然科学基金资助项目（82074104）; 中国毒理学会临床毒理课题（CST2021CT101）

Rationality of compound drug components against hypertension

GUO Shushu^1,2, JIANG Haiyan², FAN Xiaoyu², LI Wanfang^2,3, BAO Jie^2,3, MA Enlong^1#, JIN Hongtao^2,3,4,*

¹School of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China;
²New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
³Beijing Union-Genius Pharmaceutical Technology Development Co., Ltd., Beijing 100176, China;
⁴NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drug, Beijing 102206, China

Received:2024-04-28 Online:2024-09-15 Published:2024-09-14

摘要/Abstract

摘要： 目的总结已上市的复方降压药并进行组分合理性分析,探讨其成分组成及疗效评估,为复方降压药的开发和创新提供参考。方法检索国内外相关文献,对已上市的复方药物及批准的药物联合治疗方案进行分析和归纳。结果复方降压药借助多种作用机制,显著改善药物依从性,降低心血管风险,并有效降低总体治疗成本。结论复方降压药在治疗高血压中具有独特的优势,是治疗高血压和伴随疾病的更优选择,这将为复方药物的开发提供新的创新动力。

关键词: 高血压, 降压药, 复方制剂, 单片复方制剂, 药物开发, 联合治疗

Abstract: Objective To analyze the marketed combination antihypertensive drugs and the rationality of their components, explore their composition and assess their efficacy so as to provide references for the development and innovation of combination antihypertensive drugs. Methods The marketed compound drug combinations and approved drug combination therapy regimens were analyzed and summarized by searching domestic and foreign literature. Results With multiple mechanisms of action, compound antihypertensive drugs could improve drug compliance, reduce cardiovascular risks, and lower overall treatment cost. Conclusion Compound antihypertensive drugs have unique advantages in the treatment of hypertension. Compound drugs are also the best choice for the treatment of hypertension and concomitant diseases, which will provide a new impetus for the development of compound drugs in the future.

Key words: hypertension, antihypertensive drugs, compound preparation, single-pill combinations, drug development, combination therapy

中图分类号:

R916
R972

郭姝姝, 江海燕, 范潇予, 李万芳, 包捷, 马恩龙, 靳洪涛. 基于组分合理性分析高血压复方药物[J]. 中国药物警戒, 2024, 21(9): 973-977.

GUO Shushu, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, MA Enlong, JIN Hongtao. Rationality of compound drug components against hypertension[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 973-977.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240278

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/973

参考文献

[1] NGUYEN TN, CHOW CK.Global and national high blood pressure burden and control[J]. Lancet, 2021, 398(10304): 932-933.
[2] HU SS, WANG ZW.Overview of report on cardiovascular health and diseases in China 2022[J]. Chinese Journal of Cardiovascular Research(中国心血管病研究), 2023, 21(7): 577-600.
[3] AL GHORANI H, GÖTZINGER F, BÖHM M, et al. Arterial hypertension-clinical trials update 2021[J]. Nutr Metab Cardiovasc Dis, 2022, 32(1): 21-31.
[4] AL-MAKKI A, DIPETTE D, WHELTON PK, et al.Hypertension pharmacological treatment in adults: A World Health Organization guideline executive summary[J]. Hypertension, 2022, 79(1): 293-301.
[5] MANCIA G, KREUTZ R, BRUNSTRÖM M, et al. 2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension(ISH) and the European Renal Association (ERA)[J]. J Hypertens, 2023, 41(12): 1874-2071.
[6] UNGER T, BORGHI C, CHARCHAR F, et al.2020 International Society of Hypertension Global Hypertension Practice Guidelines[J]. J Hypertens, 2020, 38(6): 982-1004.
[7] WILLIAMS B, MANCIA G, SPIERING W, et al.2018 ESC/ESH Guidelines for the Management of Arterial Hypertension[J]. Eur Heart J, 2018, 39(33): 3021-3104.
[8] XIE MX, LIANG HS.Single-pill combination in essential hypertension[J]. Advances in Cardiovascular Diseases(心血管病学进展) , 2022, 43(12): 1096-1100.
[9] CHEN GL, ZHANG L, CHEN P, et al.The status and prospect of research and development of drug combinations[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(19): 2205-2210.
[10] WANG W.New trends in hypertension treatment drugs: exploration of single tablet compound formulations[J]. Journal of China Prescription Drug(中国处方药), 2015, 13(4): 30-31.
[11] SARZANI R, LAURETI G, GEZZI A, et al.Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient[J]. Ther Adv Chronic Dis, 2022, 13: 20406223221102754.
[12] PACZKOWSKA-WALENDOWSKA M, SIP S, STASZEWSKI R, et al.Single-pill combination to improve hypertension treatment: pharmaceutical industry development[J]. Int J Environ Res Public Health, 2022, 19(7): 4156.
[13] UNGER T, BORGHI C, CHARCHAR F, et al.2020 International Society of Hypertension Global Hypertension Practice Guidelines[J]. Hypertension, 2020, 75(6): 1334-1357.
[14] SUÁREZ C. Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension[J]. Drugs, 2011, 71(17): 2295-2305.
[15] SEGURA J, RUILOPE LM.A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide[J]. Vasc Health Risk Manag, 2013, 9: 521-528.
[16] WHITE WB, LITTLEJOHN TW, MAJUL CR, et al.Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension[J]. Blood Press Monit, 2010, 15(4): 205-212.
[17] WANG JG, PALMER BF, ANDERSON VK, et al.Amlodipine in the current management of hypertension[J]. J Clin Hypertens(Greenwich), 2023, 25(9): 801-807.
[18] SUNG J, AHN KT, CHO BR, et al.Adherence to triple-component antihypertensive regimens is higher with single-pill than equivalent two-pill regimens: a randomized controlled trial[J]. Clin Transl Sci, 2021, 14(3): 1185-1192.
[19] CUI Z, QIU Z, CHENG W, et al.Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: a prospective, single-arm, multi-center, real-world study[J]. J Clin Hypertens(Greenwich), 2024, 26(1): 5-16.
[20] SYED YY.Perindopril/Indapamide/Amlodipine in hypertension: a profile of its use[J]. Am J Cardiovasc Drugs, 2022, 22(2): 219-230.
[21] MCNALLY RJ, MORSELLI F, FARUKH B, et al.A review of the prescribing trend of thiazide-type and thiazide-like diuretics in hypertension: a UK perspective[J]. Br J Clin Pharmacol, 2019, 85(12): 2707-2713.
[22] BORGHI C, JAYAGOPAL PB, KONRADI A, et al.Adherence to triple single-pill combination of Perindopril/Indapamide/Amlodipine: findings from real-world analysis in Italy[J]. Adv Ther, 2023, 40(4): 1765-1772.
[23] LI ZX, ZHOU BL.New progress in the application research of sacubitril and valsartan in cardiovascular diseases[J]. Qinghai Medical Journal(青海医药杂志), 2023, 53(1): 61-64.
[24] PRZEZAK A, BIELKA W, PAWLIK A.Hypertension and type 2 diabetes-the novel treatment possibilities[J]. Int J Mol Sci, 2022, 23(12): 6500.
[25] DOCHERTY KF, VADUGANATHAN M, SOLOMON SD, et al.Sacubitril/Valsartan: Neprilysin inhibition 5 years after PARADIGM-HF[J]. JACC Heart Fail, 2020, 8(10): 800-810.
[26] GU J, NOE A, CHANDRA P, et al.Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)[J]. J Clin Pharmacol, 2010, 50(4): 401-414.
[27] GE JB, HUO Y, BAO LW, et al.Chinese expert consensus on application of fixed-dose combination pill for the prevention and treatment of cardiovascular disease[J]. Chinese Circulation Journal(中国循环杂志), 2023, 38(9): 901-910.
[28] SEVER PS, DAHLÖF B, POULTER NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial[J]. Lancet, 2003, 361(9364): 1149-1158.
[29] YUSUF S, LONN E, PAIS P, et al.Blood-pressure and cholesterol lowering in persons without cardiovascular disease[J]. N Engl J Med, 2016, 374(21): 2032-2043.
[30] LIP GY, FELMEDEN DC, DWIVEDI G. Antiplatelet agents and anticoagulants for hypertension[J]. Cochrane Database Syst Rev, 2011, 2011(12): Cd003186.
[31] VEMULAPALLI S, HELLKAMP AS, JONES WS, et al.Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the rocket AF trial[J]. American Heart Journal, 2016, 178: 74-84.
[32] MOSENZON O, ALGUWAIHES A, LEON JLA, et al.Capture: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries[J]. Cardiovasc Diabetol, 2021, 20(1): 154.
[33] ABDELBAGI O, MUSA IR, MUSA SM, et al.Prevalence and associated factors of hypertension among adults with diabetes mellitus in northern Sudan: a cross-sectional study[J]. BMC Cardiovasc Disord, 2021, 21(1): 168.
[34] KHANGURA D, KURUKULASURIYA LR, WHALEY-CONNELL A, et al.Diabetes and hypertension: clinical update[J]. Am J Hypertens, 2018, 31(5): 515-521.
[35] MA KS.The clinical effect of trimetazidine in patients with unstable angina pectoris complicated with diabetes mellitus[J]. Diabetes New World(糖尿病新世界), 2021, 24(6): 105-108.

基于组分合理性分析高血压复方药物

Rationality of compound drug components against hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙思曼, 江海燕, 范潇予, 李万芳, 包捷, 王川, 靳洪涛. 抗获得性免疫缺陷综合征复方制剂研究进展[J]. 中国药物警戒, 2024, 21(9): 978-984.
[2]	周思敏, 林建国, 王擎擎, 姚魁武. 二术天麻颗粒对临界性高血压痰湿证模型大鼠的影响[J]. 中国药物警戒, 2024, 21(9): 998-1007.
[3]	张晴, 朱磊, 蔺存莲, 解沛涛, 杨俊丽, 苏长海. 盐酸拉贝洛尔片致妊娠期高血压伴银屑病患者皮疹加重1例分析[J]. 中国药物警戒, 2023, 20(9): 1060-1063.
[4]	王荣, 刘自群, 王娜娜, 谭雄, 张怡心, 杨宽, 秦蓓. 脯氨酸丹参素冰片酯对小鼠急性毒性研究[J]. 中国药物警戒, 2023, 20(7): 754-757.
[5]	程序, 张利丹, 谢雁鸣, 高阳, 杨云云. 丹参川芎嗪注射液治疗冠心病合并高血压病联合用药的复杂网络分析[J]. 中国药物警戒, 2022, 19(12): 1325-1331.
[6]	姜睿琦, 梅升辉, 赵志刚. 性别差异对循环系统常见慢性疾病药物治疗的影响研究进展[J]. 中国药物警戒, 2022, 19(10): 1145-1148.
[7]	郑丽, 张续乾, 孙雪林, 丁辉华. 沙库巴曲缬沙坦钠治疗高血压有效性和安全性的Meta分析[J]. 中国药物警戒, 2022, 19(10): 1118-1122.
[8]	王佳域, 于丹丹, 李明, 王玲, 柳鹏程, 孙骏. 药物滥用人群曲马多复方制剂滥用/使用现状[J]. 中国药物警戒, 2020, 17(2): 98-105.
[9]	于丹丹, 孙骏, 王佳域, 吴晨, 柳鹏程. 曲马多复方制剂滥用/使用行为影响因素分析[J]. 中国药物警戒, 2019, 16(9): 543-549.
[10]	孙祯辉, 王佳域, 于丹丹, 王玲, 余正. 曲马多复方制剂滥用/使用者的性别差异调查[J]. 中国药物警戒, 2019, 16(9): 536-542.
[11]	孙祯辉, 孙骏, 王佳域, 于丹丹, 王玲, 余正. 曲马多复方制剂监管现状研究[J]. 中国药物警戒, 2019, 16(9): 528-535.
[12]	张生长, 黄伟剑. 托拉塞米联合比索洛尔对原发性高血压合并收缩性心力衰竭患者的影响及不良反应分析[J]. 中国药物警戒, 2019, 16(8): 467-472.
[13]	靳新民. 二甲双胍对高血压合并2型糖尿病患者心室重塑的影响[J]. 中国药物警戒, 2016, 13(1): 9-12.
[14]	赵敏,孙瑞芳,赵学增. 降压药物在哺乳期的合理应用[J]. 中国药物警戒, 2015, 12(5): 286-289.
[15]	钟雪,张亚同,胡欣,程刚 . 1例可疑继发性高血压患者的药学监护[J]. 中国药物警戒, 2013, 10(2): 119-121.